Market Overview

Pulse Biosciences Announces Late Breaking Oral Presentation of Sebaceous Hyperplasia Study Results at the 2019 AAD Annual Meeting

Share:

Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company
bringing to market its proprietary CellFX™ System, today announced that
clinical results from its recently completed Sebaceous Hyperplasia study
will be presented at the American Academy of Dermatology (AAD) Annual
Meeting being held March 1-5, 2019, in Washington D.C. Girish Munavalli,
M.D., M.H.S., F.A.C.M.S, of Dermatology, Laser & Vein Specialists of the
Carolinas, will present the data at the Late-Breaking Research;
Procedural Dermatology Scientific Session. The AAD Annual Meeting is one
of the largest scientific meetings of dermatologists featuring the
latest information on skin, hair and nails, presented by world-renowned
experts in the field of dermatology.

The details of the presentation are as follows:

Title: Safety and Efficacy of Nano-Pulse Stimulation in the
Treatment of Patients with Sebaceous Hyperplasia
Date and Time: Saturday
March 2, 2019 at 9:50 a.m.ET
Session: Late-Breaking
Research: Procedural Dermatology (9:00 a.m. – 11:00 a.m.ET)
Location:
Walter E. Washington Convention Center, Salon H

About Nano-Pulse Stimulation

Pulse Biosciences' patented Nano-Pulse Stimulation™ technology ("NPS™"),
delivered by its proprietary, tunable CellFX System, is characterized by
the delivery of a series of nanosecond duration electrical energy
pulses, with pulse durations from billionths up to a millionth of a
second. This unique non-thermal technology targets cellular structures
while sparing non-cellular structures, making it uniquely well-suited
for cellular targets in the dermis, such as sebaceous glands and other
adnexal structures.

About Pulse Biosciences

Pulse Biosciences is a novel medical therapy company bringing to market
its proprietary CellFX™ System. The Company's novel CellFX System
provides a precise, non-thermal delivery of nanosecond duration energy
pulses that impact cells in treated tissue while sparing non-cellular
tissue. This unique mechanism of action disrupts the functions of
internal cell structures while maintaining the outer cell membrane,
initiating a cascade of events within the cell that results in regulated
cell death. The novel characteristics of the Company's CellFX System has
the potential to significantly benefit patients across multiple medical
applications, including dermatology, the Company's first planned
commercial application. In pre-clinical studies, NPS has demonstrated an
ability to induce immunogenic cell death in several cancer cell lines.
The Company believes its NPS platform technology may play a role in
immuno-oncology as a focal tumor treatment that can initiate an adaptive
immune response. More information can be found at www.pulsebiosciences.com.

Forward-Looking Statements

All statements in this press release that are not historical are
forward-looking statements, including, among other things, statements
relating to or implying Pulse Biosciences' expectations regarding the
presentation of clinical data, commercialization of the CellFX System,
regulatory clearance and the timing of FDA filings or approvals for
products and indications, matters related to its pipeline of product
candidates, future financial performance and business strategies and
other future events. These statements are not historical facts but
rather are based on Pulse Biosciences' current expectations, estimates,
and projections regarding Pulse Biosciences' business, operations and
other similar or related factors. You should not place undue reliance on
forward-looking statements because they involve known and unknown risks,
uncertainties, and assumptions that are difficult or impossible to
predict and, in some cases, beyond Pulse Biosciences' control. Actual
results may differ materially from those in the forward-looking
statements as a result of a number of factors, including those described
in Pulse Biosciences' filings with the Securities and Exchange
Commission. Pulse Biosciences undertakes no obligation to revise or
update information in this release to reflect events or circumstances in
the future, even if new information becomes available.

CAUTION: Pulse Biosciences' CellFX System and Nano-Pulse
Stimulation (NPS) are for investigational use only.

View Comments and Join the Discussion!
 
Lightning Fast
Market News Service
$199 Free 14 Day Trial